Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yiyang Huoluo Decoction is a traditional Chinese medicine (TCM) formulation being evaluated for its safety and efficacy in treating senile atherosclerosis and coronary heart disease. Developed by researchers led by Xia Liang, the decoction is a complex mixture of twelve herbal and animal-derived ingredients, including Rehmanniae Radix, Dioscoreae Rhizoma, Cornus Officinalis Fructus, Alismatis Rhizoma, Poria Cocos, Moutan Cortex, Cinnamomi Ramulus, Astragali Radix, Angelicae Sinensis Radix, Pheretima, Persicae Semen, and Carthami Flos. It is hypothesized to promote vascular repair and improve cardiovascular function at the cellular level. In clinical studies, it is administered as oral granules in conjunction with conventional Western therapies such as antiplatelet agents and statins to address symptoms of stable angina pectoris and reduce atherosclerotic progression.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yiyang Huoluo Decoction.